Certain RCC Subgroups May Benefit From Partial vs Radical Nephrectomy

Article

In a large Chinese study, in certain RCC subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy.

Undergoing partial nephrectomy led to outcomes similar to those seen with radical nephrectomy in patients with T1b-2N0M0 renal cell carcinoma (RCC) tumors, according to the results of a recent study. However, certain subgroups of patients may obtain more benefit from a partial procedure.

“When tumor localization and technical feasibility have been taken into account, similar and even better long-term survival can be achieved with partial nephrectomy in patients with T1b-2N0M0 tumors compared to radical nephrectomy, especially when patients were male, older than 65 years, with T1b stage or clear-cell histologic type,” Mengping Zhang, of The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, and colleagues wrote in PLoS One.

While nephrectomy is still a common treatment for patients with localized RCC, there are no strong recommendations on whether to use partial or radical nephrectomy for localized RCC tumors larger than 4 cm. With this study, Zhang and colleagues wanted to examine if individual patient or tumor characteristics affected the efficacy of the two modalities.

The researchers identified 9,907 patients from the Surveillance, Epidemiology, and End Results database from 2004 to 2012. All patients had T1b-2N0M0 RCC after partial or radical nephrectomy. Propensity scores were used to balance selection bias of patients undergoing partial nephrectomy, and outcomes of partial and radical surgical procedures were compared.

Patients who underwent partial nephrectomy were significantly more likely to be male and to have smaller tumors, lower T stage, and a lower proportion of tumors with clear cell histology. After propensity score matching, preoperative characteristics were well matched.

Of the 9,907 patients, 1,418 underwent partial nephrectomy. Before propensity matching, undergoing partial nephrectomy was associated with better overall survival and cancer-specific survival compared with a radical procedure.

When the researchers looked at the 1,412 matched cohorts, partial nephrectomy was no longer associated with an improved overall survival, but the procedure was still linked with a better cancer-specific survival (hazard ratio, 1.66; 95% CI, 1.18–2.27) compared with radical nephrectomy.

Looking at certain subgroups, the data indicated that patients who were male, single, older than 65 years of age, and whose tumors had stage T1b or clear cell histology benefitted more from a partial nephrectomy procedure.

The researchers pointed out that one limitation to the study was a lack of information about comorbidities and performance status.

“It is possible that patients undergoing surgical resection may be relatively healthy at baseline and deemed fit to tolerate operation, however, potential selection bias could not be totally excluded,” the researchers wrote.

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content